View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 13, 2019updated 12 Jul 2022 11:59am

Catalent launches new clinical trial planning service

US-based Catalent has unveiled a new solution to support trial sponsors with clinical supply chain planning.

US-based Catalent has unveiled a new solution to support trial sponsors with clinical supply chain planning.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The CTSuccess clinical trial planning service is designed to reduce the risk of delays and costs as the studies progress further.

Catalent’s new CTSuccess solution uses the company’s proprietary StartScore evaluation tool to measure the complexity of a potential clinical project featuring a number of study characteristics.

Designed and developed by the company’s in-house expert team, the StartScore model is based on actual performance data.

The StartScore evaluation tool generates a risk-based score that enables sponsors to gain a better understanding of the clinical supply management.

It also enables the sponsors to start their clinical project on-time and maintain momentum upon the progression of the study.

Catalent Clinical Supply Services global director Kristen Devito said: “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise.

“Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”

Nine current good manufacturing practice (cGMP)-certified clinical packaging facilities are part of the company’s clinical supply network across Asia, Europe and North America.

Catalent also has over 50 depots in strategic locations around the world.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena